Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$11.8MCash on Hand
13.5mo Cash Runway
Follow NSRX by emailGet an email when NSRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NSRX, unsubscribe in one click. Privacy
📣 What NSRX Says Is Next
fourth quarter of 2026 · NS002: “I look forward to working with Brendan, Udi, and the entire Nasus Pharma team to support disciplined execution and to build long-term value for our shareholders.” The Company plans to initiate its pivotal clinical Phase 3 study in the fourth quarter of 2026 and have a topline data readout from that study in the first quarter of 2027.”
Company press release, Nov 16, 2026 · SEC filing
fourth quarter of 2026 · “In addition to the current study approved in the IND, Nasus Pharma plans to initiate its pivotal study in the fourth quarter of 2026 and anticipates topline data readout from the study in the first quarter of 2027.”
Company press release, Sep 14, 2026 · SEC filing
second half of 2026 · “NS005 – targeting cardiovascular diseases All programs are currently in preclinical development, with first-in-human Phase 1 studies expected to initiate in the second half of 2026 for NS003 and NS004, supporting the continued expansion of the Company’s intranasal product portfolio.”
Company press release, Mar 25, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Leadership Nasus Pharma appointed Nir Sassi as Chief Financial Officer effective November 11, 2026. Sassi previously served as CFO of Indaptus Therapeutics from August 2021 to April 2026 and of Intec Pharma. The company plans a pivotal NS002 Phase 3 study in Q4 2026. Form 6-K · SEC filing · Press release
Sep 18, 2026 ·
Financing Entered an At-The-Market sales agreement with BTIG, LLC to sell ordinary shares from time to time, with no obligation to sell any shares. Commission is up to 3.0% of gross proceeds; proceeds are for NS002 anaphylaxis development, other pipeline studies and working capital. Form 6-K · SEC filing
Sep 18, 2026 ·
Financing Nasus Pharma filed a prospectus supplement for an at-the-market offering of up to $8,500,000 of ordinary shares through BTIG, LLC, with commissions up to 3% of gross proceeds. The company is not obligated to sell any shares, and the last reported price on NYSE American was $3.53. Form 424B5 · SEC filing
Sep 14, 2026 ·
Regulatory FDA cleared the IND for NS002, an intranasal epinephrine powder for anaphylaxis. A pivotal study is planned for Q4 2026, with topline data expected in Q1 2027. Form 6-K · SEC filing · Press release
Sep 4, 2026 ·
Shareholder vote Nasus Pharma will hold its Annual and Special General Meeting on October 8, 2026, with shareholders of record as of September 14, 2026 voting on auditor re-appointment, two Class I director re-appointments, CEO Brendan P. Form 6-K · SEC filing · Press release
Sep 1, 2026 ·
Financing Nasus Pharma filed a shelf registration statement for up to $50,000,000 of ordinary shares, to be sold from time to time in future offerings at prices and terms to be set in later supplements. The filing is a preliminary prospectus, so no offering price or amounts are yet specified. Form F-3 · SEC filing
Aug 19, 2026 ·
Leadership CFO Eyal Rubin is resigning effective September 18, 2026, to pursue an opportunity outside the life science industry. Director of Finance Oren Elmaliach has been appointed interim Chief Financial Officer. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jan 2027 · Phase 1 · Recruiting · A Study to Compare the Bioavailability of Ondansetron Following Nasal (NS003) and IV Administration in Healthy Adults Registry primary completion date, not a results date
Jun 2026 · Phase 2/3 · Enrolling · FMXIN002 in Patients at Risk of Anaphylaxis Registry date passed, readout not confirmed
Also used in these trials (approved or third-party drugs, not NSRX's own candidates): Epinephrine, NS003 Ondansetron HCl microspheres powder for nasal application, Ondansetron Solution for IV infusion 8mg.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
NSRX holds $11.8M in cash and short-term investments and burns about $2.6M/quarter from operations,
an estimated runway of 13.5 months at that rate (BioRadar estimate, not company guidance).
Share count 9,015,383 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full NSRX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NSRX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.